STX Shield Therapeutics

Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous

Hardman & Co Research
Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous

12-Aug-2022 / 11:45 GMT/BST


Hardman & Co Video | Analyst interview

Shield Therapeutics (STX): Upside potential is enormous

Shield Therapeutics (STX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews.

Despite launching a drug into the US market, Shield has performed really badly over

the past 12 months, Martin explains what happened, shares his thoughts on the considerable progress made, implications for the full year, why the share price is falling, investment capital and the investment opportunity.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late stage, hospital focused pharmaceuticals.

 

Listen to the interview :

If you are interested in meeting the company, you can register your interest

Download our latest report on STX,

To contact us:

Hardman & Co
1 Frederick’s Place

London

EC2R 8AE

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall



+44 (0)203 693 7075

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1419419  12-Aug-2022 

fncls.ssp?fn=show_t_gif&application_id=1419419&application_name=news&site_id=research_pool
EN
12/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shield Therapeutics

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 3 December 2025

3rd December 2025 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: Yes...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 01/10/2025

1st October 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential** Initial...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Monthly, 1 October 2025

Hybridan Monthly, 1 October 2025 Market Comment: View from the Broker’s Desk Why you can’t compare a Defender to a Lamborghini I would always choose a Defender (90 version of course, not the Chelsea tractor new style) over a Lamborghini. Whilst many will always be taken in by the allure of brighter colours, louder engines, and slender appearance, there are some that will stay loyal to the homegrown juggernaut. It’s becoming an unfortunate common occurrence when you pick up the paper and r...

Hybridan Team
  • Hybridan Team

Hybridan Small Cap Feast: 15/09/2025

15th September 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: Henderson International Income Trust (HINT.L) left the...

Hybridan Team
  • Hybridan Team

Hybridan Small Cap Feast: 04/09/2025

Our daily digest of news from UK Small Caps 4th September 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and Closing Price on prior day to Publication. Dish of the day Admissions: Delistings: Adriatic Metals (ADT1.) has left the Main Market. What’s baki...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch